疾病干预的新靶点:嘌呤与嘧啶受体  

New Targets for Drug Therapeutics:Receptors for Purines and Pyrimidines

作　　者：任雷鸣[1] 张淼[1] 姚树坤[2] 朱忠宁[1] 

机构地区：[1]河北医科大学药学院,石家庄050017 [2]河北医科大学第四附属医院,石家庄050017

出　　处：《生理科学进展》2003年第2期116-120,共5页Progress in Physiological Sciences

基　　金：河北省自然科学基金资助课题(302481)

摘　　要：内源性核苷、核苷酸通过嘌呤与嘧啶受体 (P受体 ) ,参与机体组织器官多种功能的调节。在肿瘤、细胞凋亡、局部缺血、伤口愈合、骨质疏松、药物毒性、炎症及痛觉等病理状态下 ,P受体的内源性配体核苷与核苷酸发挥保护作用 ,P1。Endogenous nucleoside and nucleotide mediate a lot of functions via cell surface P receptors (receptors for purines and pyrimidines) in many organs. Nucleoside and nucleotide have protective roles in the events such as cancer, apoptosis, ischemia, wound healing, osteoporosis, drug toxicity, inflammation and pain. Moreover, the development of selective agonists and antagonists for P1, P2 receptors and P receptor subtypes may provide novel drugs in therapeutic strategies.

关 键 词：嘌呤与嘧啶受体 病理学 治疗学 核苷 核苷酸 

分 类 号：R363[医药卫生—病理学] Q52[医药卫生—基础医学]